Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Amarantus Bioscience Holdings (AMBS) Message Board

Cigna Agrees to Buy MDLive in Expansion of Telehea

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 30066
(Total Views: 426)
Posted On: 04/06/2021 8:23:48 PM
Avatar
Posted By: Mauibound
Cigna Agrees to Buy MDLive in Expansion of Telehealth OfferingBy 

John Tozzi
February 26, 2021, 3:05 AM HST

Pandemic has accelerated adoption of remote health care

MDLive had been planning to go public in 2021: August report

Cigna Corp. has agreed to buy MDLive Inc., a closely held telehealth provider, to expand the health-care giant’s virtual care offerings, the companies said Friday.

The deal is expected to close in the second quarter of 2021, according to an emailed statement. No terms were disclosed.

MDLive offers virtual care to more than 60 million people through health plans, according to the company’s website. The acquisition comes as Covid-19 accelerated the adoption of telehealth.

MDLive had previously been planning to go public in early 2021, its chief executive officer told Stat in August. The company had raised almost $200 million in funding, according to Crunchbase. Cigna was an earlier investor, along with other health-care companies and venture capital firms. On closing, Cigna will own 100% of MDLive, the company said.

The acquisition is one of the first deals to expand the Evernorth health services division that Cigna formed last year. Evernorth also includes pharmacy benefit manager Express Scripts and other health services businesses.

Cigna affirmed its forecast for adjusted earnings-per-share above $20 this year, including the impact of the acquisition.
https://www.forbes.com/sites/brucejapsen/2021...3c473212fe


Another article on it.

Cigna’s Evernorth To Buy Telehealth Provider MDLive

Bruce Japsen
Senior Contributor
https://www.forbes.com/sites/brucejapsen/2021...3c473212fe


(0)
(0)




Amarantus Bioscience Holdings (AMBS) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us